# 1 Long COVID in Cancer patients: Preponderance of Symptoms in Majority of Patients over

## 2 **Long Time Period**.

3

Hiba Dagher<sup>1</sup>, Anne-Marie Chaftari<sup>1</sup>, Ishwaria M. Subbiah<sup>2</sup>, Alexandre E. Malek<sup>1</sup>, Ying Jiang<sup>1</sup>, 4 Peter Lamie<sup>3</sup>, Bruno Granwehr<sup>1</sup>, Teny John<sup>1</sup>, Eduardo Yepez<sup>1</sup>, Jovan Borjan<sup>4</sup>, Cielito Reyes<sup>5</sup>, 5 Mary Flores<sup>5</sup>, Fareed Khawaja<sup>1</sup>, Mala Pande<sup>6</sup>, Noman Ali<sup>3</sup>, Raniv Rojo<sup>7</sup>, Daniel D. Karp<sup>8</sup>, Ray 6 7 Hachem<sup>1</sup>, Issam Raad<sup>1</sup> 8 9 <sup>1</sup>Department of Infectious Diseases, Infection Control and Employee Health, The University of 10 11 Texas MD Anderson Cancer Center, Houston, Texas, USA 12 13 <sup>2</sup>Integrative Medicine Program, The University of Texas MD Anderson Cancer Center, Houston, 14 Texas, USA 15 16 <sup>3</sup>Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 17 USA 18 <sup>4</sup>Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, 19 20 Texas, USA 21 22 <sup>5</sup>Emergency Medicine-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 23 24 25 <sup>6</sup>Gastroenterology Research, The University of Texas MD Anderson Cancer Center, Houston, 26 Texas, USA 27 28 <sup>7</sup>Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 29 Texas, USA 30 31 <sup>8</sup>Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 32 USA 33 34 35 Corresponding author: Anne-Marie Chaftari, Department of Infectious Diseases, Infection 36 Control and Employee Health, Unit 1460, The University of Texas MD Anderson Cancer Center, 37 1515 Holcombe Blvd., Houston, TX 77030, USA. Tel: 713-792-3491, Email: 38 achaftari@mdanderson.org 39 40 **Keywords:** Cancer patients, immunocompromised, COVID-19, long-COVID, sequelae. 41

#### 42

## 43 **Abstract:**

#### 44 Background:

- 45 An increasing number of observational studies have reported the persistence of symptoms
- 46 following recovery from acute COVID-19 disease in non-cancer patients. The long-term
- 47 consequences of COVID-19 are not fully understood particularly in the cancer patient
- 48 population. The purpose of this study is to assess post-acute sequelae of SARS-CoV-2 infection
- 49 (PASC) in cancer patients following acute COVID-19 recovery.

50

#### 51 *Methods*:

We identified cancer patients at MD Anderson Cancer Center who were diagnosed with COVID-19 disease between March 1, 2020 and Sept 1, 2020 and followed them till May 2021. To assess PASC, we collected patients reported outcomes through questionnaires that were sent to patients daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. We also reviewed patients' electronic medical records to capture the the persistence or emergence of new COVID19-related symptoms reported during any clinic or hospital encounter beyond 30 days of the acute illness and up to 14 months.

59

#### 60 *Results:*

61 We included 312 cancer patients with a median age of 57 years (18-86). The majority of

62 patients had solid tumors (75%). Of the 312 patients, 188 (60%) reported long COVID-19

63 symptoms with a median duration of 7 months and up to 14 months after COVID-19 diagnosis.

The most common symptoms reported included fatigue (82%), sleep disturbances (78%),

myalgias (67%) and gastrointestinal symptoms (61%), followed by headache, altered smell or

taste, dyspnea (47%) and cough (46%). A higher number of females reported a persistence of

67 symptoms compared to males (63% vs 37%; p=0.036). Cancer type, neutropenia,

- 68 lymphocytopenia, and hospital admission during acute COVID-19 disease were comparable in
- both groups. Among the 188 patients with PASC, only 16 (8.5%) were readmitted for COVID-
- 70 related reasons.
- 71

## 72 Conclusions:

- 73 More than one out of two cancer patients, and more likely females, report PASC that may
- 74 persist beyond 6 months and even one year. The most common symptoms are non-respiratory
- and consist of fatigue, sleep disturbance, myalgia and gastro-intestinal symptoms. Most of the
- 76 cancer patients with PASC were managed on outpatient basis with only 8,5% requiring a
- 77 COVID-19 related re-admission.

## 79 80 Introduction

80 81	Clinical outcomes of COVID-19 in patients with cancer remains an area of active study
82	with several studies showing more severe outcomes and associated risk factors such as pre-
83	existing comorbidities, cancer stage and therapy, and immunocompromised state, compared to
84	the non-cancer population <sup>1-4</sup> .
85	The earliest studies characterized the acute and sub-acute effects of COVID-19 on
86	multiple organ systems <sup>5</sup> while more recent work has raised concern on the chronic symptoms
87	attributed to COVID-19 that persist beyond the expected recovery period <sup>6,7</sup> with some
88	symptoms similar to those experienced during the recovery of other viral illnesses <sup>8-13</sup> .
89	The long-term consequences of COVID-19 remain to be fully understood and there is no
90	unequivocal consensus on the definition of post-acute sequelae of SARS-CoV-2 infection
91	(PASC), with one adopted definition being the persistence of symptoms or new delayed
92	complications that develop at least 4 weeks after a COVID-19 diagnosis <sup>7,14,15</sup> . The reported
93	prevalence of PASC widely varies from 10% up to 87% in the general population <sup>7-9,16-18</sup> and
94	there is limited data available on PASC in cancer patients and how it affects their cancer
95	progression, care and treatment.
96	Several studies suggest the persistence of symptoms past 30 days in patients with
97	severe initial COVID-19 symptoms and those that were hospitalized due to COVID-19 <sup>6,17,18</sup> ,
98	while other studies have shown a prevalence of PASC among COVID-19 outpatients as well

<sup>8,9,19</sup>. Since cancer patients fall in a higher COVID-19 risk group<sup>1</sup> and in order to provide a better 99

100	understanding of post-COVID-19 management among cancer patients, we sought to
101	characterize the patterns of long COVID-19 in the specific cancer patient population.
102 103 104	Methods
105	We identified patients with cancer receiving care at the University of Texas MD Anderson
106	Cancer Center who were also diagnosed with COVID-19 disease between March 1, 2020 and
107	Sept 1, 2020. We followed these patients as longitudinal cohort through patient-reported
108	outcomes (PRO)-based remote symptom monitoring along with usual care with clinician visits.
109	Patients were followed from March 2020 until May 31, 2021. Patient questionnaires were sent
110	out remotely daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then
111	monthly thereafter. Chart reviews were conducted for each patient's encounter that included
112	visits to our acute cancer care center, hospital re-admission, or clinic visit. Re-admissions were
113	classified as either related or non-related to COVID-19 based on the reason for hospitalization
114	as well as the reported signs and symptoms. PASC or long COVID-19 was defined as the
115	persistence of COVID-19 related symptoms beyond 30 days of diagnosis or the emergence of
116	new COVID19-related symptoms reported during a hospital or clinic encounter throughout the
117	follow-up period that extended up to 14 months. COVID-19 related symptoms included among
118	others fatigue, cough, chest tightness, dyspnea, headache, fever, altered smell or taste,
119	myalgias, gastrointestinal symptoms (such as nausea, vomiting or diarrhea), sleep disturbance,
120	and limitations with activities of daily living (ADLs).
121	

122 123	
123 124 125	Statistical analysis
126	Categorical variables were compared using chi-square or Fisher's exact test, as appropriate.
127	Continuous variables were compared using Wilcoxon rank sum test. All the tests were 2-sided
128	with a significance level of 0.05. The statistical analyses were performed using SAS version 9.4
129	(SAS Institute Inc., Cary, NC).
130 131 132 133 134 135	Results
136	Among the 602 patients who were diagnosed with COVID-19 during the study period,
137	longitudinal data was collected on 312 patients that included 188 patients who developed PASC
138	having reported symptoms that persisted at least 30 days after COVID-19 diagnosis and 124
139	who did not. The remaining patients (290) could not be followed or assessed beyond 30 days.
140	The female gender rate was significantly higher in the PASC group compared to the non-PASC
141	group (63% vs 51%; p=0.036). The age and race were similar in both groups. The median age
142	was 57 and 27% of both groups were above 65 years old. While the rate of hypertension was
143	higher in the non-PASC group (56% vs 37%; p<0.001), the rate of other comorbidities such as
144	COPD and congestive heart failures were similar in both groups. Furthermore, the type of
145	underlying cancer was similar in both groups with the majority of patients having solid tumors. In
146	addition, the rate of neutropenia, lymphocytopenia, lower respiratory tract infections, hypoxia,
147	oxygen requirement, inflammatory biomarkers, COVID-19 related hospital admissions, multi-

148	organ failure as well as medical management of COVID-19 were similar in both groups (Table
149	1). The 312 patients who were assessed beyond 30 days were followed for a median duration
150	of 7 months and up to 14 months.
151	The most commonly reported symptoms among the 188 patients who developed PASC
152	consisted of fatigue (82%), sleep disturbance (78%), myalgias (67%), gastro-intestinal
153	symptoms (62%), headache (47%), altered smell and taste (47%), dyspnea (47%) and cough
154	(46%) (Figure 1).
155	Among the 188 cancer patients who reported PASC, 59 patients (31%) were re-admitted to the
156	hospital during the follow-up period and beyond 30 days of acute illness, only 16 (8.5%) of the
157	patients with PASC had a COVID-related re-admission.
158	
159	
160	Discussion
161	Our data showed that 60% of 312 cancer patients diagnosed with COVID and
162	followed up for a median duration of 7-month [up to 14-month] developed PASC.
163	Females were more likely to report persistence of symptoms compared to
164	males. However, cancer type, age, neutropenia, lymphocytopenia, hypoxia, severe
165	disease, multiorgan failure, various interventions, or hospital admission during
166	acute COVID-19 disease were not associated with higher risk of long-COVID in

167	our study group. While hypertension was more significantly associated with no
168	PASC during follow-up. The most common PASC symptoms were fatigue, sleep
169	disturbances, myalgias and gastrointestinal symptoms. Furthermore, among PASC
170	patients who were re-hospitalized for any cause during the follow-up, the
171	admission was COVID-related in only 27%.
172	
173	In a manner similar to our current study, the CDC reported that 60% of patients
174	with immunosuppressive conditions continue to have COVID-19 symptoms
175	beyond the acute illness <sup>19</sup> . In the same CDC study, hypertension was found to be
176	significantly less often associated with PASC which is another similar finding
177	noted in our study. It is unknown from a pathophysiologic perspective as to why
178	hypertension, which is a risk factor for acute and severe COVID-19 should be less
179	associated with PASC. However given the fact that the pathogenesis of acute
180	COVID-19 is related to the interaction of the viral spike protein with the
181	angiotensin-converting enzyme 2 (ACE 2), one could postulate that this pathway
182	does not play an important role in long COVID compared to the residual

183	inflammatory processes that seem to continue to occur in PASC <sup>7,20</sup> . Similarly,
184	males are at greater risk of acute complications and death associated with acute
185	COVID-19 possibly related to higher ACE 2 expression levels in the male
186	gender <sup>20-22</sup> . However, in our study females were more likely to develop PASC also
187	suggesting a different mechanism of action for PASC besides ACE 2 expression <sup>7</sup> .
188	
189	The existing literature has also shown a higher prevalence of PASC and a longer
190	time to recovery among those with more severe COVID -19 who required hospital
191	admission and medical interventions <sup>6,17,18</sup> . However there has been several
192	reports of PASC among patients with self-reported COVID -19 who had mild
193	acute illness and were never hospitalized <sup>8,9,19,23</sup> . In our study, severe acute COVID
194	associated with hypoxia, multiorgan failure, hospital admission or underlying risk
195	factors for the progression of acute COVID-19 in cancer patients such as
196	neutropenia, lymphocytopenia, hematologic malignancy or older age were not
197	associated with increased risk of long COVID.

199	In the general population and following acute COVID-19, PASC symptoms
200	occurred at a variable rate ranging from 10% to 87% <sup>7-9,16-18</sup> . In a manner similar to
201	our results, fatigue was the most prevalent PASC symptom in many reports
202	occurring in up to 87% of COVID-19 patients compared to 82% in our patient
203	population <sup>7,9,17,18</sup> . Other common PASC symptoms reported in our study such as
204	sleep disturbances, myalgias, gastrointestinal symptoms, headache, loss of smell
205	and taste, dyspnea and cough were also widely and commonly reported in the
206	COVID-19 literature <sup>7-9,16-18</sup> . However, all of these symptoms commonly occur in
207	patients with underlying malignancy who continue to receive treatment with
208	conventional chemotherapy, radiotherapy and immunotherapy (including
209	checkpoint inhibitors). Hence, the rates of some of these PASC symptoms in the
210	cancer patient population could be exaggerated and partially related to the
211	underlying malignancy and its treatment.
212	

In our cancer patient population, PASC was not associated with a high rate of
COVID 19 related hospital admissions during the follow-up. All cause admissions

215	occurred at a rate of 31% among our cancer patients with PASC and among those
216	who were admitted only 27% were admitted because of COVID-19 related
217	reasons. Hence, among all PASC patients in our study only 8.5% were admitted
218	for COVID 19 related reasons. Furthermore, some of those few that were admitted
219	for COVID-19 related reasons could have had reinfection with a new variant
220	during the prolonged follow-up period or reactivation related to their
221	immunosuppressed status. Hence, even in our high risk cancer patient population
222	most of the symptoms associated with PASC were managed for the most part on an
223	outpatient basis without the need for hospital admission.
223 224	outpatient basis without the need for hospital admission.
	outpatient basis without the need for hospital admission. Our study has its limitations. First, the retrospective nature of this study limits any
224	
224 225	Our study has its limitations. First, the retrospective nature of this study limits any
224 225 226	Our study has its limitations. First, the retrospective nature of this study limits any firm conclusions about factors directly contributing to PASC in our COVID-19
224 225 226 227	Our study has its limitations. First, the retrospective nature of this study limits any firm conclusions about factors directly contributing to PASC in our COVID-19 cancer patients. Second, this is a single center study which could also limit the

231	several confounding causes of hospital admissions and overlapping symptoms in
232	cancer patients that may be due to their underlying disease, aggressive treatments
233	and comorbidities present their own challenge in identifying PASC among cancer
234	patients post their COVID-19 diagnosis.
235 236	In conclusion, long COVID occurred in the majority of our cancer patients
237	diagnosed with acute COVID-19 with a preponderance of symptoms (such as
238	fatigue, sleep disturbances, and gastrointestinal symptoms) over a long time
239	period. Most of the patient's with long COVID/PASC were fairly and adequately
240	managed on outpatient basis without the need for hospital admission. Besides the
241	female gender, we found no other underlying condition or severity of illness during
242	acute COVID-19 that would predict PASC.
0.40	

#### Table 1. Comparing COVID-19 cancer pateints with and without long-term symptoms (at least 30 days after their COVID-19 diagnosis).

Variables	Having PASC		<i>p</i> -value
	No	Yes	
	(n=124)	(n=188)	
	N (%)	N (%)	
Age (years), meidan (range)	57 (18-85)	57 (21-86)	0.47
Age ≥ 65	33 (27)	50 (27)	> .99
Gender			0.036
Male	61 (49)	70 (37)	
Female	63 (51)	118 (63)	
Race			0.45
Caucasian	66 (53)	102 (54)	
Black	24 (19)	26 (14)	
Hispanic	28 (23)	52 (28)	
Asian	5 (4)	8 (4)	
Other	1 (1)	0 (0)	
Prior COPD/Bronchiolitis obliterans	4 (3)	7 (4)	> .99
History of hypertension	70 (56)	69/187 (37)	< .001
History of heart failure	3 (2)	5/186 (3)	> .99
Type of cancer			0.92
Hematological malignancy	31 (25)	48 (26)	
Solid tumor	93 (75)	140 (74)	
Hypoxia at diagnosis	25 (20)	23/180 (13)	0.08
Oxygen flow at diagnosis			0.20
High flow	6/30 (20)	6/43 (14)	
Low flow	15/30 (50)	15/43 (35)	
None	9/30 (30)	22/43 (51)	
Non-invasive ventilation at diagnosis	16 (13)	13/179 (7)	0.10
Lab values at COVID-19 diagnosis			
ALC < 1 K/uL	44/74 (59)	57/94 (61)	0.88
ANC < 0.5 K/uL	5/75 (7)	5/89 (6)	> .99
Hemoglobin < 10 g/dL	23/65 (35)	16/78 (21)	0.06
LDH ≥ 250 U/L	29/58 (50)	41/67 (61)	0.21
D-dimer ≥ 1 mcg/ml	28/54 (52)	27/61 (44)	0.42
Ferritin ≥ 500 ng/ml	30/54 (56)	36/59 (61)	0.56
$CRP \ge 40 \text{ mg/L}$	32/56 (57)	43/63 (68)	0.21
IL-6 ≥ 25 pg/ml	18/41 (44)	20/48 (42)	0.83
LRTI at diagnosis or progression to LRTI	29 (23)	35/182 (19)	0.38
COVID-related hospital admission	53 (43)	68 (36)	0.24
Remdesivir treatment	17 (14)	18 (10)	0.26
L-6 pathway inhibitors - Tocilizumab	8 (6)	5 (3)	0.10
Convalescent plasma	8 (6)	15 (8)	0.61

Steroids	18 (15)	19 (10)	0.24
Multi-organ failure	6/121 (5)	8/180 (4)	0.84

Note:

(Just let you know) A multivariate logistic regrssion analysis showed histroy of hypertension was the only factor

that was indepdently associated with long-term symptoms (p<.001), but as a protector (OR=0.43,

95% CI=0.27 to 0.69), not as a risk factor.


244

245

246

247





## 253 ACKNOWLEDGMENTS

- 254 We thank Ms. Salli Saxton, Department of Infectious Diseases, Infection Control and Employee Health,
- 255 MD Anderson Cancer Center, Houston, for helping with the submission of the manuscript.
- 256 This research was supported by the National Institutes of Health/National Cancer Institute under award
- 257 number P30CA016672, which supports MD Anderson Cancer Center's Clinical Trials Office.

259	Refe	rences
260		
261	1.	Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-
262		2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783-
263		791.
264	2.	Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and
265		critical illness among 5279 people with coronavirus disease 2019 in New York City:
266	_	prospective cohort study. BMJ. 2020;369:m1966.
267	3.	Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
268		Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases
269		From the Chinese Center for Disease Control and Prevention. JAMA.
270		2020;323(13):1239-1242.
271	4.	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
272		with COVID-19 in Wuhan, China: a retrospective cohort study. <i>Lancet.</i>
273	~	2020;395(10229):1054-1062.
274	5.	Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19.
275	e	Nat Med. 2020;26(7):1017-1032.
276 277	6.	Barman MP, Rahman T, Bora K, Borgohain C. COVID-19 pandemic and its recovery time of patients in India: A pilot study. <i>Diabetes Metab Syndr.</i> 2020;14(5):1205-1211.
278	7.	Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. <i>Nat Med.</i>
279	7.	2021;27(4):601-615.
280	8.	Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a
281	0.	single-centre longitudinal study. <i>Clin Microbiol Infect.</i> 2021;27(1):89-95.
282	9.	Goertz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a
283	0.	SARS-CoV-2 infection: the post-COVID-19 syndrome? <i>ERJ Open Res.</i> 2020;6(4).
284	10.	Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of
285		severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus
286		outbreaks after hospitalisation or ICU admission: A systematic review and meta-
287		analysis. J Rehabil Med. 2020;52(5):jrm00063.
288	11.	Hui DS, Joynt GM, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS)
289		on pulmonary function, functional capacity and quality of life in a cohort of survivors.
290		Thorax. 2005;60(5):401-409.
291	12.	Kausler DH, Lichty W, Hakami MK, Freund JS. Activity duration and adult age
292		differences in memory for activity performance. <i>Psychol Aging</i> . 1986;1(1):80-81.
293	13.	Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression
294		and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC
295		Neurol. 2011;11:37.
296	14.	Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of
297		Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health
298	45	Implications. JAMA. 2020;324(22):2251-2252.
299	15.	Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute
300	16	covid-19 in primary care. <i>BMJ</i> . 2020;370:m3026.
301 302	16.	Bowles KH, McDonald M, Barron Y, Kennedy E, O'Connor M, Mikkelsen M. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of
302		Home Health Recipients. Ann Intern Med. 2021;174(3):316-325.
303	17.	Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in
304	17.	Patients After Acute COVID-19. <i>JAMA</i> . 2020;324(6):603-605.
306	18.	Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs
307		in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol.
308		2021;93(2):1013-1022.

- Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for
  Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate
  Health Care Systems Network United States, March-June 2020. MMWR Morb Mortal
  Wkly Rep. 2020;69(30):993-998.
- 313 20. Kaseb AO, Mohamed YI, Malek AE, et al. The Impact of Angiotensin-Converting
  314 Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection.
  315 Pathogens. 2021;10(3).
- 316 21. Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on 317 Severity and Mortality. *Front Public Health.* 2020;8:152.
- Viveiros A, Rasmuson J, Vu J, et al. Sex differences in COVID-19: candidate pathways,
  genetics of ACE2, and sex hormones. *Am J Physiol Heart Circ Physiol.*2021;320(1):H296-H304.
- 321 23. Tenforde MW, Billig Rose E, Lindsell CJ, et al. Characteristics of Adult Outpatients and
  322 Inpatients with COVID-19 11 Academic Medical Centers, United States, March-May
  323 2020. MMWR Morb Mortal Wkly Rep. 2020;69(26):841-846.